Cluster B Several psychedelics companies are out to target depression, anxiety, PTSD, and substance use disorder – but surprisingly we don’t hear much about personality disorders. Despite an…
Taylor Gavinchuk
Numinus (NUMI.V) is gaining somewhat of a cult-like following among retail investors. People see an undervalued company with competitive advantages, and from an ethics standpoint, a company conducting…
TBI 2X Stanley Cup winner Daniel Carcillo recently announced his Chicago-based company Wesana Health is set to go public next month. The company completed a $4M CAD convertible note…
Early money Generating revenue as a new company is almost always difficult. It typically takes time to build up a loyal customer base, execute marketing campaigns and create awareness…
As far back as I can remember, I always wanted to be a trader I remember when I first started buying stocks, I was 16 using a family member’s…
Shamans among the machines In his 1999 lecture titled ‘Shamans Among the Machines’ Terence McKenna pointed out that “as far as people and machines are concerned, it was Ludwig…
Earlier this month I wrote a piece on Field Trip (FTRP.C) scaling their ketamine clinics after a huge $95M raise. I liked their business model, and Novamind’s (NM.C) is…
There are two options when it comes to ingesting psychedelics, natural or synthetic. People have been tripping balls eating raw natural mushrooms for thousands of years, so why…
Canada: not a big push for rec Canada is a country typically at the forefront of forward-thinking movements in health and science. With the recent legalization of cannabis…
Billionaire Warren Buffett made his money in the market largely by betting on the idea of the American Dream working out. And while the reality of that dream still…